Sunitinib versus interferon-á in metastatic RCC

Motzer and colleagues presented updated results from a multicentre, phase III trial of sunitinib versus interferon-á as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.

Download full article